Tolvaptan for hyponatremia in patients with cirrhosis: a post hoc subgroup analysis of a multicenter, randomized, double-blind, placebo-controlled trial

Hepatology International · Published 2026-05-29 · DOI 10.1007/s12072-026-11093-5

Authors (26)

Yu Wang, Huifen Wang, Jun Cheng, Weijiang Ye, Huiguo Ding, Cunliang Deng, Guiqiang Wang, Haihang Zhu, Chengwei Chen, Guozhong Gong, Dazhi Zhang, Qing Xie, Mobin Wan, Xiong Cai, Jun Li, Qing Mao, Yongping Chen, Junqi Niu, Hao Wang, Yiming Mao, Yuwang Tian, Mingji Xian, Yuanyuan Kong, Hong Ma, Xiaojuan Ou, Jidong Jia

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Wang, Y., Wang, H., Cheng, J., et al. (2026). Tolvaptan for hyponatremia in patients with cirrhosis: a post hoc subgroup analysis of a multicenter, randomized, double-blind, placebo-controlled trial. Hepatology International. https://doi.org/10.1007/s12072-026-11093-5

Related articles

• Clinical trial endpoints for metabolic dysfunction and alcohol associated steatotic liver disease · Hepatology International · 2026 · Same journal
• APASL clinical practice guidelines on the management of chronic hepatitis B infection: a 2026 update · Hepatology International · 2026 · Same journal
• APASL STC on Wilson Disease; New Delhi 2026 · Hepatology International · 2026 · Same journal
• Phosphatidylethanol versus clinical criteria to diagnose alcohol use relapse after liver transplantation: a prospective cohort study · Hepatology International · 2026 · Same journal
• Precision medicine for G-CSF in ACLF: the biomarker gap · Hepatology International · 2026 · Same journal
• Response to letter to editor—Machine learning prediction of rapid HBsAg seroclearance at week 24 in inactive carriers treated with pegylated interferon · Hepatology International · 2026 · Same journal
• Methodological Considerations in the MAFLD-MASLD Dichotomy for Cardiac Risk Assessment · Hepatology International · 2026 · Same journal
• Obstructive sleep apnea mediates the association between body mass index and metabolic dysfunction-associated steatotic liver disease in patients with obesity · Hepatology International · 2026 · Same journal
• Gout is independently associated with occult hepatic fibro-inflammation independent of obesity: a multi-cohort study using MRI-cT1 and elastography · Hepatology International · 2026 · Same journal
• FXR overexpression promotes liver regeneration through inducing FGF2 activation in APAP-induced acute liver injury · Hepatology International · 2026 · Same journal